RecruitingNCT06678919

AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Enrollment

500 participants

Start Date

Oct 31, 2024

Study Type

OBSERVATIONAL

Conditions

Metastatic Colorectal Cancer (Mcrc)

Summary

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study tracks the real-world outcomes of people with metastatic colorectal cancer (colon or rectal cancer that has spread) who are receiving third-line treatment or beyond — meaning they have already tried at least two prior rounds of chemotherapy. The goal is to understand what works best at this advanced stage. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of metastatic colorectal cancer - You have already received at least 2 prior treatment regimens including standard chemotherapy agents and targeted therapies - You are starting or currently on a third or later line of treatment **You may NOT be eligible if...** - You have not yet tried at least two prior treatment regimens - You are unwilling to have your treatment data recorded for research purposes - You do not meet the specific prior treatment criteria defined by the registry Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.